TWEAK has been shown to induce NF-κB signaling and participate in immune-mediated inflammatory conditions, such as SLE, rheumatoid arthritis, inflammatory bowel disease and psoriasis [46,47]. Here, NFKB1 is linked to systemic lupus erythematosus.